MNK's one year PEG ratio, measuring expected growth in earnings next year relative to current common stock price is 0.29 -- higher than just 5.39% of US-listed equities with positive expected earnings growth.
The price/operating cash flow metric for Mallinckrodt plc is higher than merely 3.51% of stocks in our set with a positive cash flow.
MNK's price/sales ratio is 0.07; that's higher than the P/S ratio of just 3.3% of US stocks.
If you're looking for stocks that are quantitatively similar to Mallinckrodt plc, a group of peers worth examining would be OSMT, SCOR, ROSE, CPLG, and AR.
Mallinckrodt plc Ordinary Shares (MNK) Company Bio
Mallinckrodt Public Limited Company is a global specialty biopharmaceutical and medical imaging business that develops, manufactures, markets and distributes specialty pharmaceutical products and medical imaging agents. Areas of focus include therapeutic drugs for autoimmune and rare disease specialty areas like neurology, rheumatology, nephrology and pulmonology, neonatal critical care respiratory therapies, and analgesics and central nervous system drugs. The company was founded in 2013 and is based in Dublin, Ireland.
MNK Price Forecast Based on DCF Valuation
DCF Fair Value Target:
We started the process of determining a valid price forecast for Mallinckrodt plc with a discounted cash flow analysis -- the results of which can be found in the table below. To summarize, we found that Mallinckrodt plc ranked in the 87th percentile in terms of potential gain offered. Moreover, under all the scenarios we modelled, the output consistently forecasted positive returns. In terms of the factors that were most noteworthy in this DCF analysis for MNK, they are:
4% of the company's capital comes from equity, which is greater than only 1.42% of stocks in our cash flow based forecasting set.
Mallinckrodt plc's interest coverage rate -- a measure of gross earnings relative to interest payments -- comes in at -4.32. This coverage rate is greater than that of only 12.33% of stocks we're observing for the purpose of forecasting via discounted cash flows.
The weighted average cost of capital for the company is 18. This value is greater than 99.57% stocks in the Healthcare sector that generate free cash flow.
Terminal Growth Rate in Free Cash Flow
Return Relative to Current Share Price
For other companies in the Healthcare that have a similar discounted cashflow valuation profile (and ensuing price forecasts) as MNK, try ARGX, SUPN, ASRT, ASNB, and BEAT.
DUBLIN--(BUSINESS WIRE)--The "Radiopharmaceutical - Global Market Outlook (2019-2027)" report has been added to ResearchAndMarkets.com's offering. The Global Radiopharmaceutical market accounted for $3.76 billion in 2019 and is expected to reach $5.99 billion by 2027 growing at a CAGR of 6.0% during the forecast period. Some of the key factors propelling market growth are technological advancements in the diagnostics sector, increasing prevalence of cancer, and increasing applications of molecu
Beyond Air, Inc. (XAIR) is a biopharmaceutical company developing medical devices that deliver nitric oxide ((NO)) to treat respiratory conditions and tumors. XAIR hasn't flown below the radar of the coronavirus hype, the name was up over 100 percent year-to-date in early March. Based on comments at a March investor...
In this article you are going to find out whether hedge funds think Mallinckrodt Public Limited Company (NYSE:MNK) is a good investment right now. We like to check what the smart money thinks first before doing extensive research on a given stock. Although there have been several high profile failed hedge fund picks, the consensus […]
Mallinckrodt plc (NYSE: MNK), a global biopharmaceutical company, will present on Tuesday, June 23, 2020 at the BMO Prescriptions for Success Healthcare Conference. Mark Trudeau, President and Chief Executive Officer, and Bryan Reasons, Executive Vice President and Chief Financial Officer, will represent the company in a fireside chat at 8:00 a.m. Eastern Time. To access the webcast, please refer to the webcast link posted on our site at: http://www.mallinckrodt.com/investors. A replay of the fireside chat will also be available following the meeting.